{"database":"MetabolomicsWorkbench","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["http://www.metabolomicsworkbench.org/rest/study/study_id/ST000344/mwtab"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Metabolomics"],"technology_type":["Mass Spectrometry","ESI"],"species":["Mesocricetus Auratus"],"full_dataset_link":["http://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&StudyID=ST000344"],"study_factor":["Treatment:Lipid Supplement","Treatment:Control"],"tissue":["Cultured Cells"],"submitter_affiliation":["University of California, Davis"],"sample_protocol":["RP POSITIVE ION MODE. RP NEGATIVE ION MODE."],"repository":["MetabolomicsWorkbench"],"metabolite_name":["1_LPC (17:0) iSTD","FA (26:0)","Ceramide (d34:2)","PC (36:2)","PE (36:2)","PC (42:2)","PC (p-34:0) or PC (o-34:1)","Ceramide (d40:2)","SM (d36:1)","1_MG (17:0/0:0/0:0) iSTD","1_SM (d18:1/17:0) iSTD","SM (d40:0)","PE (p-32:1) oe PE (o-32:2)","PC (p-36:0) or PC (o-36:1)","PE (34:1)","Ceramide (d34:1)","PC (40:1)","Ceramide (d40:1)","FA (14:0)","SM (d34:0)","SM (d34:1)","1_DG (18:1/2:0/0:0) iSTD","1_Ceramide C17 iSTD","SM (d40:1)","Gal-Gal-Cer(d18:1/16:0) or Lactosylceramide(d18:1/16:0)","FA (20:0)","PC (38:2)","FA (17:0) B","FA (17:0) A","Ceramide (d34:0)","PE (34:2)","Ceramide (d40:0)","Ceramide (d42:2)","1_CE (22:1) iSTD","1_Sphingosine (d17:1) iSTD","FA (15:0)","Lactosylceramide (d18:1/24:1(15Z))","SM (d34:2)","PC (28:0)","1_PC (12:0/13:0) iSTD","1_LPE (17:1) iSTD","Ceramide (d36:1)","FA (20:1)","PE (32:1)","PC (42:1)","PC (36:1)","PC (p-34:3) or PC (o-34:4)","PE (p-36:2) or PE (o-36:3)","Ceramide (d42:1)","PC (p-36:1) or PC (o-36:2)","1_PE (17:0/17:0) iSTD","SM (d42:2) A","PC (p-34:1) or PC (o-34:2) B","FA (18:1)","FA (22:0)","GlcCer (d38:1)","PC (38:4) B","PC (32:2)","1_CUDA (pos) iSTD","Ceramide (d42:0)","PC (30:0)","1_Cholesterol d7 iSTD","SM (d32:1)","1_MAG (17:0/0:0/0:0) iSTD","GlcCer (d42:1)","FA (22:1)","1_PC (25:0) iSTD","PE (p-36:1) or PE (o-36:2)","FA (18:0)","LPC (16:0)","PC (32:3)","PC (30:1)","1_TG (17:0/17:1/17:0)-d5 iSTD","1_CUDA iSTD","GlcCer (d42:2)","Ceramide (d38:1)","FA (24:0)","Ceramide (d42:2) A","PC (p-36:3) or PC (o-36:4)","1_Ceramide (d18:1/17:0) iSTD","PC (40:2)","PE (p-34:1) or PE (o-34:2)","PC (32:0)","1_SM (d35:1) iSTD","FA (16:1)","1_PG (17:0/17:0) iSTD","PE (p-34:2) or PE (o-34:3)","FA (24:1)","GlcCer (d40:1)","SM (d42:0)","1_DG (12:0/12:0/0:0) iSTD","1_FA (16:0)-d3 iSTD","Ceramide (d32:1)","LPC (18:0) B","PE (36:1)","PC (32:1)","FA (16:0)"],"data_protocol":[""],"name_synonyms":["biochemical pathways, Nutriceutical, Metabolic Process, degradation, Process, Processes, metabolism resulting in cell growth, Metabolic Concepts, Dietary Supplement, Metabolic Processes, Anabolism., Nutraceuticals, Concept, Metabolic Phenomena, Metabolism Concepts, Nutraceutical, Metabolism, Phenomena, Concepts, secretion, Metabolism Concept, Supplement, Phenomenon, Supplementations, Metabolism Phenomena, metabolism, Food Supplementations, Metabolic Phenomenon, Dietary Supplementations, multicellular organism metabolic process, biodegradation, Metabolic, Herbal Supplements, catabolism, Dietary, Nutriceuticals, Metabolic Concept, metabolic process resulting in cell growth, Herbal, Food, Supplements, Food Supplement, Food Supplements, biotransformation, Neutraceutical, Food Supplementation, Catabolism, Nutritional supplement, Neutraceuticals, Herbal Supplement"],"sample_synonyms":["iones., Ionen, ion, Ion, ions, iones"],"additional_accession":[]},"is_claimable":false,"name":"Effects of dietary supplement on hamster metabolism","description":null,"dates":{"publication":""},"accession":"ST000344","cross_references":{"TAXONOMY":["10036"]}}